Newsroom

PT Aurogen Pharma Indonesia, a step-down subsidiary of Aurobindo Pharma Limited, India, is pleased to announce that it has completed the acquisition of the marketing authorizations and assets related to specific 17 brands from UpJohn & Viatris, which they were marketing in Indonesia. This deal will provide the company an excellent entry platform into the fast-growing pharmaceutical market of Indonesia with a good revenue base and product portfolio. The revenue from the acquired brands stood at US$ 30.5 million in calendar year 2022. PT Aurogen Pharma Indonesia will continue to use the services of the existing sales & marketing team, who will be inducted into its rolls from December 15, 2023. For additional background on the acquisition, please refer to our announcement on September 12, 2023 here. Commenting on the development, Mr. K Nithyananda Reddy, Vice Chairman & Managing Director, Aurobindo Pharma Limited said “This deal marks our foray into the pharmaceutical market of the world’s fourth largest populous country. This is also in-line with our long-term strategy of diversifying towards untapped growth markets. We look forward to beginning a smooth integration of the business and aim to deliver consistent quality products, services and value to our patients and customers.” 

About PT Aurogen Pharma Indonesia

PT Aurogen Pharma Indonesia was incorporated in November 2022 as a step-down subsidiary of Aurobindo Pharma Limited, India. PT Aurogen will start business activities with effect from December 15, 2023, starting with the acquired products from Upjohn & Viatris Indonesia. It has a GWP compliant warehouse and PBF license for distribution activities from BPOM (the Indonesian Food and Drug Authority), effective August 2023.

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up. To know more, please log on to www.aurobindo.com For further information or queries, please contact: